Phase 2 N=73 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Esophageal Cancer
Primary: Number of Subjects Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 5; 21; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=97 A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
Pain, Inflammatory
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 2; 2; 4; 6 Participants
Phase 1 N=12 AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Primary: Number of Participants With Dose-limiting Toxicities (DLT) — 0 Participants
Phase 3 N=393 Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment — 20.6; 9.7 Months
Early Phase 1 N=53 ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Stricture Urethra
Primary: Rate of Treatment Related Serious Complication — 0 percentage of participants
Phase 1 N=19 A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Mesothelioma
Primary: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) During Cycle 1, Per Common Terminology Criteria for Adverse Events (AEs), Version 5.0 (CTCAE) — 2…
N/A N=30 Continuous Quantified EEG in NeuroIntensive Care
Coma · Traumatic Brain Injury · Subarachnoid Hemorrhage
Primary: Number of Correct qEEG Evaluations — 70; 78; 69; 82 percentage of correct evaluation
Phase 1 N=107 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
Arthritis, Rheumatoid · Healthy
Primary: Part 1: Cmax After the First and Last Dose — 1.59; 7.70; 9.87; 18.0 microgram (µg)/ millilitre (mL)
Phase 3 N=30,415 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
SARS-CoV-2
Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001
Phase 2 N=22 Bone Material Comparison in Maxillary Sinus Augmentation
Alveolar Bone Resorption · Sequela · Tooth Extrusion
Primary: Bone Density - Limited View CBCT (Cone-beam Computed Tomography) Measurements — 14.4; 1.5 percentage of bone height shrinkage
N/A N=412 Survey of Attitudes and Factors Associated With CPR in an Older Population
Cardiac Arrest
Primary: Measure the Intent to Engage in CPR Training or Intent to Perform CPR — 3.6; 4.1 score on a scale
Phase 1 N=12 Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants
Inflammatory Bowel Disease
Primary: Maximum Observed Concentration (Cmax) of PF-06480605 — 41530 nanogram per milliliter (ng/mL)
Phase 1 N=21 A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
Tobacco Use Disorder
Primary: Maximum Observed Plasma Nicotine Concentration (Cmax) of NicoDerm CQ Dungarvan (Test) Compared to NicoDerm CQ, Alza (Reference) — 23.554; 24.478 Nanograms per milliliter…
N/A N=36 Pilot Trial of Mobile Mantram Delivery
PTSD
Primary: Eligibility Rate — 38 Participants
Phase 1 N=41 Assessment of KAN-101 in Celiac Disease (ACeD)
Celiac Disease
Primary: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) — 4; 3; 2; 3 Participants